Floatz logo

Vorbipiprant

Metastatic GI Cancers

Rottapharm BiotechSmall moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

72 Active assets in the Metastatic GI Cancers cohort.

Asset / SponsorPhaseRating
DEXAMETHASONE
Cedars-Sinai Medical Center
Phase 4BB
Irinotecan
Amgen
Phase 2BB
FLUOROURACILUM
Alliance for Clinical Trials in Oncology
Phase 2BB
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE
Brian Anderson, MD
Phase 4BB
Epinephrine
Cedars-Sinai Medical Center
Phase 4BB

View all 50 →

Same molecule, other indications

Vorbipiprant is also rated in:

colorectal carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
Mismatch Repair Protein ProficientDormant
CCC
Indicative ·
48 / 100
View asset →
colorectal cancerDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →